A user experienced hairline improvement after four weeks on 1.5mg dutasteride but had side effects like reduced libido and sensitive nipples. They plan to switch to finasteride to manage these side effects.
The user shared a 4-month update on hair loss treatment using finasteride, minoxidil, and derma stamps, showing significant progress. The user experienced no side effects and plans to continue the treatment, updating monthly.
A 36-year-old considering a fourth hair transplant is advised to either shave his head or use a hair system due to poor results from previous transplants and late medication use. He plans to consult top surgeons and adjust his current treatments, including finasteride and minoxidil.
SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.
The conversation discusses using a violet ray device for hair regrowth, citing a case where zinc ion treatments showed promising results. It also mentions similar devices like the Growcombr and niostem helmet.
A 40-year-old shared his 4-month hair regrowth progress using oral dutasteride, topical minoxidil once nightly, and weekly microneedling. He experienced significant shedding initially but showed noticeable improvement, receiving positive feedback.
The user experienced a sudden and severe hair loss after 1.5 years of successful treatment with finasteride and minoxidil. They plan to check their thyroid and vitamin D levels as potential causes.
Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.
The conversation discusses a hair loss treatment regimen including finasteride, dutasteride, minoxidil, tretinoin, microneedling, and red light therapy. The user plans to update on progress after eight months.
PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.
A user experienced significant hair regrowth after 4 months using topical finasteride and minoxidil, along with dermastamping and biotin supplements, without side effects. They are not considering a hair transplant due to the success of this regimen.
Suvomipic, previously known as PP405, is progressing to Phase 3 trials for hair loss treatment. Its effectiveness compared to existing treatments like Minoxidil and Finasteride is still uncertain.
OP used finasteride, topical minoxidil, microneedling, and caffeine shampoo for hair loss. After 4 months, they saw progress with new, lighter-colored hairs.
The user reported gradual hair regrowth after 4 months using oral finasteride, topical minoxidil, dermastamping, and vitamins C and D3. They noted the use of a 1.25mm dermastamp and discussed sourcing finasteride in Canada.
Clascoterone (Breezula) is anticipated for release in the coming years but is considered too weak for aggressive androgenetic alopecia (AGA). Current treatments like minoxidil, finasteride, and dutasteride are preferred, with some users obtaining clascoterone from the gray market.
A user shared their 4-month hair regrowth progress using 0.5mg dutasteride and 2.5mg minoxidil, reporting no side effects and significant improvement. The conversation includes discussions on treatment choices, dosages, and personal experiences with hair loss treatments.
Fluridil was abandoned due to its weak effectiveness and low binding affinity to the androgen receptor, making it less competitive against DHT and testosterone. Users discuss its limited results compared to other treatments like pyrilutamide and RU58841.
The user shared their 4.5-month progress using oral finasteride, topical minoxidil, and oral dutasteride, along with biotin, vitamin D, saw palmetto, and multivitamins. They use a combination of finasteride and dutasteride weekly, with micro-stamping, to address hair loss.
A user shared their 4-month progress using a topical solution with 5% minoxidil and 0.1% finasteride, applied twice daily. They reported good results despite occasional missed applications.
DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.
A user shared progress pictures showing improvement from NW 6 to NW 2 after four months of treatment. They are considering using exosomes to further reverse hair miniaturization.
Fluridil degrades androgen receptors, which are prevalent in the scalp and other tissues. People with androgenetic alopecia (AGA) may have higher expression of these receptors and 5AR activity in affected scalp areas.
PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.
A user shared their 4-year progress using 1mg daily finasteride for hair loss, noting significant improvement without side effects. They did not use minoxidil tablets due to availability issues but are satisfied with their results.
JXL082 is not the same as PP405, leading to a halt in sales and a plan to synthesize the real PP405. There is skepticism about the safety and effectiveness of JXL082 and PP405, with concerns about patent issues and the long-term impact on hair growth.
A user stopped hair loss after taking finasteride daily for four years, with minimal regrowth and no side effects. They believe stress initially caused their hair loss.
A 40-year-old user reports promising hairline improvement after 4 months of using 1mg finasteride daily and 5% minoxidil foam 2-2.5 times daily. The hairline vellus hair appears to be turning terminal.
The user shared their 4-month progress using finasteride, topical minoxidil, and dermarolling, noting noticeable hair regrowth. They experienced occasional low libido as a side effect and use Regro brand products.
Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.